Live Analyst Rating Changes 34513 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Laura Sutcliffe
Citi

Laura Sutcliffe

Citi
Wall Street Analyst
★★☆☆☆
#2756
on 13Foresight · ranked by our own returns
67%
Success Rate
+5.0%
Average Return
44 of 66 calls profitable · +14.6% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 67% of Laura Sutcliffe's ratings turned a profit when each position was held for 1 year — averaging +5.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

61 Buy 58 Hold 4 Sell
Laura's Stock Coverage 27 ratings · 2026-09-25
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
 Sep 24, 2026 HOLD Strong Buy
+27.6% avg upside
11 analysts
$33.00
4.47% Upside
 · ·
AU:TLX
Telix Pharmaceuticals
 Sep 23, 2026 BUY Strong Buy
+65.9% avg upside
14 analysts
$31.00
94.89% Upside
 · ·
AU:PME
Pro Medicus Limited
 Sep 23, 2026 BUY Buy
+57.6% avg upside
9 analysts
$225.00
39.73% Upside
 · ·
AU:CSL
CSL
 Sep 23, 2026 HOLD Strong Buy
+21.2% avg upside
16 analysts
$160.00
9.57% Downside
 · ·
RMD
Resmed
 Sep 10, 2026 HOLD Buy
+4.2% avg upside
27 analysts
$240.00
8.84% Upside
 +2.5% ·
AU:ANN
Ansell
 Sep 10, 2026 HOLD Hold
-20.0% avg upside
9 analysts
$39.50
10.59% Downside
 +2.4% ·
AU:SHL
Sonic Healthcare Limited
 Sep 10, 2026 HOLD Buy
+33.9% avg upside
12 analysts
$22.00
17.10% Upside
 +1.3% ·
AU:RHC
Ramsay Health Care
 Sep 10, 2026 HOLD Buy
-14.1% avg upside
14 analysts
$49.00
11.33% Downside
 +3.4% ·
AU:COH
Cochlear
Sep 10, 2026 HOLD Buy
+32.4% avg upside
15 analysts
$140.00
1.70% Downside
 -0.2% ·
NL:LKFT
Lakefront Biotherapeutics NV
 May 07, 2024 HOLD Sell
+90.0% avg upside
17 analysts
$34.00
28.55% Upside
 -16.5% ·
CH:NOVN
Novartis AG
 Dec 14, 2022 HOLD Buy
-6.0% avg upside
32 analysts
$84.00
29.90% Downside
 +10.5% ·
FR:SAN
Sanofi
 Aug 09, 2022 HOLD Strong Buy
+34.6% avg upside
30 analysts
$103.00
43.98% Upside
 +15.8% ·
SAN
Banco Santander SA
 Aug 09, 2022 HOLD Buy
-54.9% avg upside
9 analysts
 — +55.6% ·
GB:GSK
GlaxoSmithKline
 Aug 08, 2022 HOLD Hold
+3.8% avg upside
26 analysts
$1820.00
2.26% Downside
 -16.0% ·
GB:0NZT
UCB SA
 Jun 27, 2022 HOLD Strong Buy
+5.3% avg upside
19 analysts
$87.00
58.83% Downside
 -1.5% ·
GB:0MGB
Genmab A/S
 May 20, 2022 BUY Strong Buy
-8.1% avg upside
25 analysts
$2600.00
14.30% Upside
 +30.1% ·
GMAB
Genmab
 Mar 16, 2022 BUY Strong Buy
+82.6% avg upside
27 analysts
 — +0.5% ·
NVS
Novartis
 Nov 05, 2021 HOLD Buy
-2.5% avg upside
24 analysts
 — +1.8% ·
ARGX
Argenx Se
 Jun 18, 2021 BUY Strong Buy
-13.4% avg upside
48 analysts
$390.00
59.64% Downside
 +10.0% ·
LKFT
Lakefront Biotherapeutics
 Apr 12, 2021 HOLD Buy
+238.3% avg upside
25 analysts
$88.08
195.17% Upside
 -14.6% ·
DE:MRK
Merck KGaA
 Feb 28, 2020 HOLD Buy
+3.7% avg upside
34 analysts
$108.00
20.46% Downside
 +24.4% ·
SNY
Sanofi
 Aug 14, 2019 BUY Strong Buy
+78.0% avg upside
20 analysts
 — +25.0% ·
GSK
GlaxoSmithKline
 Feb 22, 2019 HOLD Hold
-12.2% avg upside
20 analysts
 — +11.6% ·
NVO
Novo Nordisk
 Aug 08, 2018 HOLD Hold
+199.7% avg upside
26 analysts
$300.00
676.65% Upside
 +10.3% ·
LLY
Eli Lilly & Co
 Jul 25, 2018 HOLD Strong Buy
-8.5% avg upside
49 analysts
$99.00
91.66% Downside
 +14.2% ·
BMY
Bristol-Myers Squibb
 Oct 26, 2017 HOLD Buy
+0.1% avg upside
42 analysts
$55.00
10.54% Downside
 -15.0% ·
GILD
Gilead Sciences
 Oct 18, 2017 BUY Strong Buy
-21.1% avg upside
66 analysts
$96.00
35.15% Downside
 -4.5% ·
🔒 22 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Laura Sutcliffe — Frequently Asked Questions
How accurate are Laura Sutcliffe's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Laura's ratings were profitable over a one-year hold, with an average return of +5.0% per rating, or +14.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Laura ranked on 13Foresight?
Laura Sutcliffe is currently ranked #2756 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Laura cover?
Laura most recently has ratings on AU:RMD, AU:TLX, AU:PME, AU:CSL, RMD, AU:ANN, AU:SHL, AU:RHC, AU:COH, NL:LKFT, CH:NOVN, FR:SAN and 15 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.